BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec
Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...
SHA: 603259
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO)...
WuXi AppTec Denies Unauthorized IP Transfer Allegations Amidst Strong Financial Performance
WuXi AppTec (SHA: 603259, HKG: 2359), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO)...
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...
WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift
The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...
US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data
The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign...
WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...
US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns
US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...
WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies
A bipartisan bill introduced on January 26, 2024, by members of the US House Select...
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China
WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
CORXEL Partners with WuXi STA for Sterile Nasal Spray Production
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...
WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...
WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...